Atara Biotherapeutics, Inc. (ATRA)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ATRA). Investors who purchased Atara shares are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Atara violated federal securities laws.
On July 12, 2022, Atara issued a press release updating the market on its preliminary analysis phase 2 EMBOLD study for product candidate ATA188. Atara stated, “Based on the analysis of the EMBOLD data available at the time of the IA [interim analysis], there was not a sufficient dataset to draw conclusions about the predictive value of six months EDSS improvement for 12 months EDSS improvement. The IDSMC [Independent Data and Safety Monitoring Committee] believes the six-month interim endpoint may be an inaccurate measure of the potential of this intervention in this condition.” Following this news, Atara stock dropped sharply.
If you are aware of any facts relating to this investigation or purchased Atara shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.